A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

NCT01314872 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1395

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: Vibegron
DRUG: Tolterodine ER
DRUG: Placebo matching vibegron
DRUG: Placebo matching tolterodine ER

Sponsor

Merck Sharp & Dohme LLC